Evidence map›Paper›PMID 40389717›Full record

ArticleMolecular diversity2026

Synthesis, anti-tumor evaluation, and mechanistic investigation of 3-indolylpyrazole phenoxyacetamide derivatives against chronic myeloid leukemia cells.

Mengting Liu, Guiyun Wu, Yue Zhou, Chengpeng Li, Danping Chen, Yan Li, Zhurui Li, Chenchen Li, Zhenchao Wang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mengting LiuCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Guiyun WuCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Yue ZhouCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Chengpeng LiCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Danping ChenCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Yan LiCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China.
Zhurui LiCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China. li-zhurui@163.com.
Chenchen LiCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China. chenchenli@hnu.edu.cn.
Zhenchao WangCollege of Pharmacy, Guizhou University, Guiyang, 550025, Guizhou, China. wzc.4884@163.com.

Funding

Guizhou Provincial Foundation for Excellent Scholars Program GCC [2023]072Key Project of Guizhou Province Basic Research Program ZD[2025]071National Key Research and Development Program of China 2023YFD1400403National Natural Science Foundation of China 22364008National Natural Science Foundation of China 32260694National Natural Science Foundation of China 32360689Natural Science Foundation of Guizhou Province ZK[2022]073Natural Science Foundation of Guizhou Province ZK[2024]074Natural Science Foundation of Guizhou Province ZK[2024]100
6 · The paper itself

Abstract

Both indole and phenol structures are important active components of drug structure. In this study, a series of novel 3-indole pyrazole derivatives incorporating phenolic moieties were rationally designed and synthesized through molecular hybridization strategy. A comprehensive evaluation of antitumor activity demonstrated that these target compounds exhibited remarkable cytotoxicity across four distinct cancer cell lines. Notably, compound O11 emerged as the most potent compound, showing exceptional activity against human chronic myeloid leukemia (K562) cells with an IC

Indexed as

AcetamidesAntineoplastic AgentsIndolesLeukemia, Myelogenous, Chronic, BCR-ABL PositivePyrazolesApoptosisCell CycleCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansK562 CellsNF-kappa BReactive Oxygen SpeciesSignal TransductionStructure-Activity RelationshipAcetamidesAntineoplastic AgentsIndolesNF-kappa BPyrazolesReactive Oxygen SpeciesAnticancerApoptosisIndoleNF-κB signaling pathway

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.